Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Study Contact
- Phone Number: 1-800-843-2020
- Email: tkarkkai@its.jnj.com
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- VRC
-
Jacksonville, Florida, United States, 32218
- Dr. James Weber & Associates, PA - City Square Blvd
-
Longwood, Florida, United States, 32779
- Pearson Research Center, PA
-
Maitland, Florida, United States, 32751
- Maitland Vision Center - North Orlando Ave
-
-
New York
-
Vestal, New York, United States, 13850
- Sacco Eye Group
-
-
Ohio
-
Powell, Ohio, United States, 43065
- Luxe Vision and Optical
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02888
- Dr. David W. Ferris & Associates
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Be at least 40 years of age and not greater than 70 years of age at the time of consent.
- Own a wearable pair of spectacles if required for their distance vision.
- Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 30 days or more duration).
- Either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, monovision or multifocal contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".
- The subject's distance spherical equivalent refraction must be in the range of +1.00 to +4.00 or -1.00 D to -4.00 D in each eye.
- The subject's refractive cylinder must be ≤0.75 D in each eye.
- The subject's ADD power must be in the range of +0.75 D to +2.50 D.
- The subject must have distance best corrected visual acuity of 20/20-3 or better in each eye.
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Be currently pregnant or lactating.
- Have any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
- Have been diagnosed with diabetes.
- Have any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This includes, but not be limited to, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
- Have any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy, peripheral iridotomy/iridectomy, cataract surgery, retinal surgery, etc.).
- Have a history of amblyopia, strabismus or binocular vision abnormality.
- Use of any of the following medications within 1 week prior to enrollment: oral retinoid, oral tetracyclines, anticholinergics, oral phenothiazines, oral/inhaled corticosteroids. See section 9.1 for further examples.
- Be currently using any ocular medications with the exception of rewetting drops.
- Have a history of herpetic keratitis.
- Have a history of irregular cornea.
- Have a history of pathological dry eye.
- Have participated in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
- Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild, sibling of the employee or their spouse) of the clinical site.
- Have any known hypersensitivity or allergic reaction to non-preserved rewetting drop solutions or sodium fluorescein.
- Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
- Have any current ocular infection or inflammation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Test/Control/Control
Eligible subjects will be randomized into the Test/Control/Control sequence.
|
Test Lens
Control Lens
|
|
Experimental: Control/Test/Test
Eligible subjects will be randomized into the Control/Test/Test sequence.
|
Test Lens
Control Lens
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
High Luminance, High Contrast (HLHC) Binocular logMAR Visual Acuity at distance (4 meters)
Time Frame: 1-week follow-up
|
Visual acuity after approximately 1-week in the optimized lens pair under HLHC illuminance conditions will be evaluated at distance (4 meters) using ETDRS Charts.
|
1-week follow-up
|
|
High Luminance, High Contrast (HLHC) Binocular logMAR Visual Acuity at intermediate (64 cm)
Time Frame: 1-week follow-up
|
Visual acuity after approximately 1-week in the optimized lens pair under HLHC illuminance conditions will be evaluated at intermediate (64 cm) using reduced Guillon-Poling charts.
|
1-week follow-up
|
|
High Luminance, High Contrast (HLHC) Binocular logMAR Visual Acuity at near (40 cm)
Time Frame: 1-week follow-up
|
Visual acuity after approximately 1-week in the optimized lens pair under HLHC illuminance conditions will be evaluated at near (40 cm) using reduced Guillon-Poling charts.
|
1-week follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Johnson & Johnson Vision Care, Inc. Clinical Trial, Johnson & Johnson Vision Care, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR-6612
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.